Search

Topical doxycycline for corneal neovascularisation

Six eyes with corneal vascularisation were treated with 1% topical doxycycline, four times a day for three weeks. The patients were reviewed at various intervals over a period of one year. The eyes selected had neovascularisation secondary to a variety...

Late stromal rejection in DALK

This case series reported on late stromal rejections in eyes after uncomplicated deep anterior lamellar keratoplasties (DALKs). Four eyes of three patients experienced episodes of isolated stromal rejection 33 to 46 months after surgically uncomplicated DALKs and a minimum of...

Comparison of treatment regimes for APROP

The authors evaluated the risk factors and treatment outcomes of various treatment options for APROP including intra-vitreal anti-VEGF injections, laser treatment and a combination of both. This was an observational study of all consecutive cases of untreated APROP from 2018-19...

Type 3 CNV and anti-VEGF

The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is...

Outcomes of reinjection of Ranibizumab for reactivation of retinopathy of prematurity

The authors present their data from Egypt assessing the effects of Ranibizumab reinjection for neonates with retinopathy of prematurity (ROP). Doses given were 0.25mg/0.025mL. They screened 2318 infants with 115 (5%) of infants with a mean post menstrual age (PMA)...

Treat-and-extend regimen in treatment of patients with type 3 neovascularisation

Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...

Intravitreal ranibizumab for the treatment of myopic CNV

The authors conducted a prospective study. Sixty-four patients (65 eyes) attended the 12-month follow-up examination. The mean patient age was 47.8 years. Fifty-five patients (86.0%) were females. All patients had pathologic myopia (a spherical equivalent of more than − 6.0...

Progression of myopic maculopathy after treatment

The authors report on a retrospective study carried out to evaluate long-term progression of myopic maculopathy and functional outcome in eyes treated for myopic choroidal neovascularisation (CNV) and in eyes without CNV. Fifty-four myopic eyes of 30 patients were included...

Type 3 macular neovascularisation (MNV) due to age-related macular degeneration

This paper systematically reviews and summarises the current knowledge on type 3 neovascularisation due to age-related macular degeneration which is defined as neovascularisation originating from the retinal deep capillary plexus that grows towards the outer retina often penetrating the level...

ROP anti-VEGF treatment review

The purpose of this review was to consider data relating to risks and benefits of the use of anti-VEGF treatment for retinopathy of prematurity (ROP) over the past five years of 2015-2020. Ocular benefits include treatment of aggressive posterior ROP,...

Platelet rich fibrin membrane for descemetocele

This case series described the use of a novel technique in the treatment of descemetocele. Three patients developed descemetoceles following infective keratitis with impending risk of corneal perforation. Platelet rich fibrin (PRF) membrane was prepared using 8ml of fresh venous...